Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by G1945Von Apr 24, 2023 10:35am
71 Views
Post# 35410302

RE:Promis to present at conference

RE:Promis to present at conference
retiredcop wrote: This is what I am looking forward to this week ...we have had very little info on the vaccine 

Title: Rational Design of a Vaccine for Alzheimer’s Disease Using Computationally-Derived Conformational B Cell Epitopes to Selectively Target Toxic Amyloid-Beta Oligomers
Session: S26: Experimental Therapeutics in Dementia (abstract #4532)
Presenter: Dr. Johanne Kaplan
Date & Time: April 25, 2023 at 1:36 p.m. ET


The news release of September 22, 2022, did give us some information about the vaccine.

https://d1io3yog0oux5.cloudfront.net/_c3909589c54dbb5cb2db2e2aad5f3a0f/promisneurosciences/news/2020-09-22_ProMIS_Neurosciences_to_develop_multivalent_34.pdf


"A vaccine capable of inducing an effective antibody response against amyloid-beta toxic oligomers (ABOs) could be administered prophylactically to at-risk individuals to prevent the development of symptomatic disease. Additionally, the vaccine could be given therapeutically to individuals living with a diagnosis of AD to inhibit further disease." (bolding added)

What is not spelled out is how often is the vaccine administered.

G1945V
<< Previous
Bullboard Posts
Next >>